Trials / Conditions / Post-kala-azar Dermal Leishmaniasis

Post-kala-azar Dermal Leishmaniasis

10 registered clinical trials studyying Post-kala-azar Dermal Leishmaniasis — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by F NCT07506967	Kenya Medical Research Institute	N/A
Completed	Repurposing Ivermectin for PKDL Treatment NCT06251739	International Centre for Diarrhoeal Disease Research, Bangladesh	EARLY_Phase 1
Withdrawn	A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis ( NCT04107961	University of York	Phase 2
Completed	Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan NCT05449717	Epicentre	—
Completed	Ivermectin Repurposed for the Treatment of PKDL NCT07286604	International Centre for Diarrhoeal Disease Research, Bangladesh	EARLY_Phase 1
Completed	Miltefosine for Children With PKDL NCT02193022	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 3
Completed	Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh NCT03311607	Medecins Sans Frontieres, Netherlands	Phase 4
Completed	A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical NCT01975051	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 4
Completed	Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL NCT00982774	Access to Advanced Health Institute (AAHI)	Phase 1
Completed	Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in Indi NCT00486382	Access to Advanced Health Institute (AAHI)	Phase 1